Please assess the completion status of the following clinical trial:

Trial Title: Primary Prophylaxis of Gastric Varix Bleed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with GOV2 with eradicated esophageal varix or IGV1, who had never bled from gastric varix were included.~Exclusion Criteria:~* Only esophageal varix, GOV1 with GOV2, acute bleed or past history of bleed from gastric varix, contraindications to beta-blocker therapy and cyanoacrylate injection.~* Prior injection of cyanoacrylate or sclerotherapy or variceal ligation or transjugular intrahepatic portosystemic shunt or balloon-occluded retrograde transvenous obliteration or balloon-occluded endoscopic injection sclerotherapy of gastric varix for prevention of bleeding from GV~* Patients already on beta-blocker or nitrates~* Undetermined origin of bleeding from esophageal varix or gastric varix~* Hepatic encephalopathy grade III/IV~* Hepatorenal syndrome~* Hepatocellular carcinoma~* Presence of deep jaundice (serum bilirubin \> 10 mg/dl)~* Uremia~* Cerebrovascular accident~* Cardiorespiratory failure~* Pregnancy and patients not giving informed consent for endoscopic procedures

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Endoscopic Cyanoacrylate injection (Type: ACTIVE_COMPARATOR): Endoscopic injection of cyanoacrylate in the gastric varix until obturation
- No Intervention (Type: NO_INTERVENTION): No treatment offered for gastric varix
- Beta-blocker (propranolol) (Type: OTHER): Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.

Based on this trial design, predict the completion outcome and termination type (if applicable).